HbO2 Therapeutics Overview

  • Founded
  • 2014
Founded
  • Status
  • IPO Registration
  • Employees
  • 8
Employees
  • Latest Deal Type
  • IPO
  • (Announced)
  • Latest Deal Amount
  • $30M
Latest Deal Amount

HbO2 Therapeutics General Information

Description

Developer of human and veterinary hemoglobin-based oxygen carriers designed to help stabilize the patient and prevent tissue damage or organ dysfunction associated with oxygen deprivation. The company's oxygen carriers when intravenously administered, increase the oxygen-carrying capacity of the blood, enabling healthcare providers to treat their patients and improve their quality of life.

Contact Information

Ownership Status
In IPO Registration
Financing Status
Venture Capital-Backed
Primary Industry
Medical Supplies
Primary Office
  • 674 Souder Road
  • Souderton, PA 18964
  • United States
+1 (267) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

HbO2 Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. IPO 26-Apr-2022 $30M 00.00 Announced Generating Revenue
3. Debt - PPP 27-Apr-2020 00.00 Completed Generating Revenue
2. Seed Round 13-Apr-2015 $2.75M $5.5M Completed Generating Revenue
1. Angel (individual) 13-Mar-2015 $2.75M $2.75M Completed Startup
To view HbO2 Therapeutics’s complete valuation and funding history, request access »

HbO2 Therapeutics Patents

HbO2 Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20070219335-A1 Exposing to glutaraldehyde and sodium borohydride; buffer includes sodium lactate, sodium chloride or n-acetyl-l-cysteine; increased molecular weight; improves yield of synthetic blood Granted 27-Jan-2004 00000000 00
US-7459535-B2 Exposing to glutaraldehyde and sodium borohydride; buffer includes sodium lactate, sodium chloride or n-acetyl-l-cysteine; increased molecular weight; improves yield of synthetic blood Expired - Fee Related 27-Jan-2004 00000000 00
US-7135554-B1 Exposing the stabilized hemoglobin solution to glutaraldehyde to further polymerize at least a portion of the hemoglobin present in the stabilized hemoglobin solution, whereby the average molecular weight of stabilized hemoglobin solution increases to thereby produce the polymerized hemoglobin solution Expired - Fee Related 27-Jan-2004 00000000 00
US-20090137762-A1 Method of forming a polymerized hemoglobin solution from stabilized hemoglobin Abandoned 27-Jan-2004 00000000 00
US-20030165573-A1 Hemoglobulin blood substitute Granted 28-Feb-2002 A61K35/18 00
To view HbO2 Therapeutics’s complete patent history, request access »

HbO2 Therapeutics Executive Team (3)

Name Title Board Seat Contact Info
Gerald Kowalski Co-Founder and Chairman
Zafiris Zafirelis Co-Founder, President and Chief Executive Officer
Igor Serov Chief Financial Officer
To view HbO2 Therapeutics’s complete executive team members history, request access »

HbO2 Therapeutics Board Members (1)

Name Representing Role Since
Gerald Kowalski HbO2 Therapeutics Co-Founder and Chairman 000 0000
To view HbO2 Therapeutics’s complete board members history, request access »

HbO2 Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial